ClexBio Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Investors
-
12
ClexBio General Information
Description
Developer of a preclinical tissue therapeutics company designed to develop bioengineered human blood vessels for transplant. The company utilizes tissue engineering and single-cell techniques by combining advanced bio-fabrication approaches with hydrogel technology to develop vascular tissue, enabling researchers to provide patient-specific blood vessels for preclinical and clinical applications.
Contact Information
Website
www.clexbio.comCorporate Office
- Lørenveien 73
- C/o Parallell
- 0585 Oslo
- Norway
Corporate Office
- Lørenveien 73
- C/o Parallell
- 0585 Oslo
- Norway
ClexBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 22-Nov-2024 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2022 | Completed | Generating Revenue | |||
| 4. Seed Round | 20-Jul-2021 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Jan-2021 | Completed | Generating Revenue | |||
| 2. Grant | 05-Aug-2020 | $1M | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ClexBio Patents
ClexBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4817643-A1 | Vascularized supportive matrix | Pending | 31-Mar-2025 | ||
| WO-2026209622-A1 | Vascularized supportive matrix | Pending | 31-Mar-2025 | ||
| WO-2026109621-A1 | Cell culture apparatus for producing tissues | Pending | 21-Nov-2024 | ||
| EP-4252790-A1 | Use of polymer-based microcarriers in the production of tissue scaffolds with complex geometry | Inactive | 30-Mar-2022 | ||
| EP-4499160-A1 | Use of polymer-based microcarriers in the production of tissue scaffolds with complex geometry | Active | 30-Mar-2022 | A61L27/52 |
ClexBio Signals
ClexBio Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EQT Foundation | Impact Investing | Minority | ||
| DNB Bank | Corporation | |||
| Angel (individual) | Minority | |||
| Iaso Ventures | Venture Capital | Minority | ||
| Angel (individual) | Minority |
ClexBio FAQs
-
When was ClexBio founded?
ClexBio was founded in 2018.
-
Where is ClexBio headquartered?
ClexBio is headquartered in Oslo, Norway.
-
What is the size of ClexBio?
ClexBio has 9 total employees.
-
What industry is ClexBio in?
ClexBio’s primary industry is Drug Discovery.
-
Is ClexBio a private or public company?
ClexBio is a Private company.
-
What is ClexBio’s current revenue?
The current revenue for ClexBio is .
-
How much funding has ClexBio raised over time?
ClexBio has raised $1.2M.
-
Who are ClexBio’s investors?
EQT Foundation, DNB Bank, , Iaso Ventures, and are 5 of 12 investors who have invested in ClexBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process